Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. [electronic resource]
Producer: 20171024Description: 525-533 p. digitalISSN:- 1179-1918
- Aged
- Antineoplastic Agents -- therapeutic use
- Cost-Benefit Analysis
- Drug Costs
- Female
- Gastrointestinal Neoplasms -- drug therapy
- Gastrointestinal Stromal Tumors -- drug therapy
- Humans
- Imatinib Mesylate -- therapeutic use
- Male
- Middle Aged
- Phenylurea Compounds -- therapeutic use
- Pyridines -- therapeutic use
- Quality-Adjusted Life Years
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.